Literature DB >> 19592488

NDRG4 is required for cell cycle progression and survival in glioblastoma cells.

Stephen H Schilling1, Anita B Hjelmeland, Daniel R Radiloff, Irwin M Liu, Timothy P Wakeman, Jeffrey R Fielhauer, Erika H Foster, Justin D Lathia, Jeremy N Rich, Xiao-Fan Wang, Michael B Datto.   

Abstract

NDRG4 is a largely unstudied member of the predominantly tumor suppressive N-Myc downstream-regulated gene (NDRG) family. Unlike its family members NDRG1-3, which are ubiquitously expressed, NDRG4 is expressed almost exclusively in the heart and brain. Given this tissue-specific expression pattern and the established tumor suppressive roles of the NDRG family in regulating cellular proliferation, we investigated the cellular and biochemical functions of NDRG4 in the context of astrocytes and glioblastoma multiforme (GBM) cells. We show that, in contrast to NDRG2, NDRG4 expression is elevated in GBM and NDRG4 is required for the viability of primary astrocytes, established GBM cell lines, and both CD133(+) (cancer stem cell (CSC)-enriched) and CD133(-) primary GBM xenograft cells. While NDRG4 overexpression has no effect on cell viability, NDRG4 knockdown causes G(1) cell cycle arrest followed by apoptosis. The initial G(1) arrest is associated with a decrease in cyclin D1 expression and an increase in p27(Kip1) expression, and the subsequent apoptosis is associated with a decrease in the expression of XIAP and survivin. As a result of these effects on cell cycle progression and survival, NDRG4 knockdown decreases the tumorigenic capacity of established GBM cell lines and GBM CSC-enriched cells that have been implanted intracranially into immunocompromised mice. Collectively, these data indicate that NDRG4 is required for cell cycle progression and survival, thereby diverging in function from its tumor suppressive family member NDRG2 in astrocytes and GBM cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592488      PMCID: PMC2757219          DOI: 10.1074/jbc.M109.012484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours.

Authors:  J Felsberg; P S Yan; T H-M Huang; U Milde; J Schramm; O D Wiestler; G Reifenberger; T Pietsch; A Waha
Journal:  Neuropathol Appl Neurobiol       Date:  2006-10       Impact factor: 8.090

2.  Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc.

Authors:  T Okuda; H Kondoh
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

3.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.

Authors:  Masaki Uematsu; Ikuroh Ohsawa; Toshiyuki Aokage; Kiyomi Nishimaki; Kouji Matsumoto; Hiroshi Takahashi; Sadamitsu Asoh; Akira Teramoto; Shigeo Ohta
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  The Drg-1 gene suppresses tumor metastasis in prostate cancer.

Authors:  Sucharita Bandyopadhyay; Sudha K Pai; Steven C Gross; Shigeru Hirota; Sadahiro Hosobe; Kunio Miura; Ken Saito; Therese Commes; Sunao Hayashi; Misako Watabe; Kounosuke Watabe
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 6.  A genecentric Human Protein Atlas for expression profiles based on antibodies.

Authors:  Lisa Berglund; Erik Björling; Per Oksvold; Linn Fagerberg; Anna Asplund; Cristina Al-Khalili Szigyarto; Anja Persson; Jenny Ottosson; Henrik Wernérus; Peter Nilsson; Emma Lundberg; Asa Sivertsson; Sanjay Navani; Kenneth Wester; Caroline Kampf; Sophia Hober; Fredrik Pontén; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2008-10       Impact factor: 5.911

7.  NDRG1 is necessary for p53-dependent apoptosis.

Authors:  Susanne Stein; Emily K Thomas; Birger Herzog; Matthew D Westfall; Jonathan V Rocheleau; Roger S Jackson; Mai Wang; Peng Liang
Journal:  J Biol Chem       Date:  2004-09-17       Impact factor: 5.157

8.  Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells.

Authors:  Hai-Ning Zhen; Li-Wen Li; Wei Zhang; Zhou Fei; Chang-Hong Shi; Tong-Tao Yang; Wen-Tao Bai; Xiang Zhang
Journal:  Int J Oncol       Date:  2007-11       Impact factor: 5.650

9.  A novel homocysteine-responsive gene, smap8, modulates mitogenesis in rat vascular smooth muscle cells.

Authors:  Shinichi Nishimoto; Junko Tawara; Hitoshi Toyoda; Kunihiro Kitamura; Toshi Komurasaki
Journal:  Eur J Biochem       Date:  2003-06

10.  NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells.

Authors:  Young Jun Kim; Sun Young Yoon; Jong-Tae Kim; Seung Cheol Choi; Jong-Seok Lim; Joo Heon Kim; Eun Young Song; Hee Gu Lee; Inpyoi Choi; Jae Wha Kim
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

View more
  24 in total

1.  NDRG4 protein-deficient mice exhibit spatial learning deficits and vulnerabilities to cerebral ischemia.

Authors:  Hitomi Yamamoto; Koichi Kokame; Tomohiko Okuda; Yukako Nakajo; Hiroji Yanamoto; Toshiyuki Miyata
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

2.  Let-7f Regulates the Hypoxic Response in Cerebral Ischemia by Targeting NDRG3.

Authors:  Yaobing Yao; Weiwei Wang; Lijun Jing; Yiwen Wang; Mingzhe Li; Xiaocan Hou; Jing Wang; Tao Peng; Junfang Teng; Yanjie Jia
Journal:  Neurochem Res       Date:  2016-11-04       Impact factor: 3.996

Review 3.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

4.  NDRG4 is downregulated in glioblastoma and inhibits cell proliferation.

Authors:  Wenchao Ding; Jing Zhang; Jae-Geun Yoon; Dongyan Shi; Gregory Foltz; Biaoyang Lin
Journal:  OMICS       Date:  2012-04-10

5.  Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas.

Authors:  Peyman Karimi Goudarzi; Farzad Mehrabi; Reza Jalili Khoshnood; Ali Baradaran Bagheri; Koorosh Ahmadi; Emad Yahaghi; Hesam Abdolhoseinpour
Journal:  Tumour Biol       Date:  2015-11-30

6.  Cortical Auditory Deafferentation Induces Long-Term Plasticity in the Inferior Colliculus of Adult Rats: Microarray and qPCR Analysis.

Authors:  Cheryl Clarkson; M Javier Herrero-Turrión; Miguel A Merchán
Journal:  Front Neural Circuits       Date:  2012-11-26       Impact factor: 3.492

7.  Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor.

Authors:  Jungwon Hwang; Yoonjeong Kim; Ho Bum Kang; Lukasz Jaroszewski; Ashley M Deacon; Hwiseop Lee; Won-Chan Choi; Kyung-Jin Kim; Cheol-Hee Kim; Beom Sik Kang; Jie-Oh Lee; Tae-Kwang Oh; Jae Wha Kim; Ian A Wilson; Myung Hee Kim
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

8.  NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients.

Authors:  Dake Chu; Zixi Zhang; Yi Zhou; Yunming Li; Shaojun Zhu; Jian Zhang; Qingchuan Zhao; Gang Ji; Weizhong Wang; Jianyong Zheng
Journal:  Oncotarget       Date:  2015-04-10

9.  Whole-exome sequencing studies of nonfunctioning pituitary adenomas.

Authors:  Paul J Newey; M Andrew Nesbit; Andrew J Rimmer; Rosie A Head; Caroline M Gorvin; Moustafa Attar; Lorna Gregory; John A H Wass; David Buck; Niki Karavitaki; Ashley B Grossman; Gilean McVean; Olaf Ansorge; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

10.  NDRG1 regulates osteosarcoma cells via mediating the mitochondrial function and CSCs differentiation.

Authors:  Tong Zhao; Ying Meng; Yongping Wang; Wenji Wang
Journal:  J Orthop Surg Res       Date:  2021-06-07       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.